Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 74.7%

Neg 0% Neu 0% Pos 74.7%

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.